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Abstract Nonsyndromic orofacial clefts (OFC) are com-
mon birth defects caused by certain genes interacting with
environmental factors. Mutations and association studies
indicate that the homeobox gene MSX1 plays a role in
human clefting. In a Dutch case-control triad study
(mother, father, and child), we investigated interactions
between MSX1 and the parents’ periconceptional lifestyle
in relation to the risk of OFC in their oVspring. We studied
181 case- and 132 control mothers, 155 case- and 121 con-
trol fathers, and 176 case- and 146 control children, in
which there were 107 case triads and 66 control triads. Uni-
variable and multivariable logistic regression analyses were
applied, and odds ratios (OR), 95% conWdence intervals
(CI) were calculated. Allele 4 of the CA marker in the
MSX1 gene, consisting of nine CA repeats, was the most
common allele found in both the case and control triads.
SigniWcant interactions were observed between allele 4
homozygosity of the child with maternal smoking (OR 2.7,
95% CI 1.1–6.6) and with smoking by both parents (OR
4.9, 95% CI 1.4–18.0). Allele 4 homozygosity in the
mother and smoking showed a risk estimate of OR 3.2
(95% CI 1.1–9.0). If allele 4 homozygous mothers did not
take daily folic acid supplements in the recommended per-
iconceptional period, this also increased the risk of OFC for
their oVspring (OR 2.8, 95% CI 1.1–6.7). Our Wndings
show that, in the Dutch population, periconceptional smok-
ing by both parents interacts with a speciWc allelic variant
of MSX1 to signiWcantly increase OFC risk for their
oVspring. Possible underlying mechanisms are discussed.
Introduction
Orofacial clefts (OFC) are common birth defects and
include nonsyndromic cleft lip (CL) and/or cleft palate
(CP). They have a birth prevalence varying from 1 in 1,500
to 1 in 2,500 in Caucasian populations (Schutte and Murray
1999). These Wgures also depend on ethnic background,
geographic origin, lifestyle factors and socioeconomic sta-
tus (Jugessur and Murray 2005). OFC are most often classi-
Wed into cleft lip with or without cleft palate (CL/P) and
cleft palate only (CPO). The etiology of OFC is complex,
meaning both genetic and environmental factors are
involved (Jugessur and Murray 2005; Krapels et al. 2006a;
D. de Costa and I. P. C. Krapels have equally contributed to this work.
M.-J. H. van den  Boogaard · D. de Costa · R. J. Sinke · D. Lindhout
Department of Medical Genetics, 
University Medical Center Utrecht, Utrecht, The Netherlands
e-mail: m.j.h.vandenboogaard@umcutrecht.nl
D. de Costa · R. P. M. Steegers-Theunissen (&)
Department of Obstetrics and Gynecology, 
Erasmus MC, University Medical Center, 
PO Box 2040, 3000 CA Rotterdam, The Netherlands
e-mail: R.steegers@erasmusmc.nl
F. Liu · C. van Duijn · R. P. M. Steegers-Theunissen
Department of Epidemiology, Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands
R. P. M. Steegers-Theunissen
Department of Pediatric Cardiology, Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands
R. P. M. Steegers-Theunissen
Department of Clinical Genetics, Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands
I. P. C. Krapels
Department of Clinical Genetics, 
Academic Hospital Maastricht, Maastricht, The Netherlands123
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expression studies and a transgenic knock-out model with
cleft phenotype have suggested that Msx1 is involved in the
etiology of clefting (Satokata and Maas 1994; Davidson
1995).
Msx1 is a highly conserved homeobox gene that plays
several key roles in epithelial–mesenchymal tissue inter-
actions during craniofacial development. It regulates cellular
proliferation, diVerentiation and cell death, which is impor-
tant for balanced cell growth and morphogenesis (Bendall
and Abate-Shen 2000). Extensive studies in knockout mice
have also demonstrated that Msx1-Bmp signaling, regula-
ting expression of Shh, is essential for palate development
(Zhang et al. 2002) and the identiWcation of a MSX1 stop
mutation in a Dutch family with a combination of tooth
agenesis and OFC conWrmed MSX1 as a candidate gene for
clefting in humans (van den Boogaard et al. 2000).
Sequencing- and association studies have indicated a role
for MSX1 in the etiology of nonsyndromic orofacial clef-
ting (Lidral et al. 1998; Beaty et al. 2001; Blanco et al.
2004; Fallin et al. 2003; Jezewski et al. 2003; Jugessur
et al. 2003; Vieira et al. 2003; Moreno et al. 2004; Vieira
et al. 2005; Modesto et al. 2006; Tongkobpetch et al. 2006;
Park et al. 2007), although results published by others ques-
tion this role (Mitchell et al. 2001; Koillinen et al. 2003;
Etheredge et al. 2005).
There is increasing evidence that the environment can
substantially modulate genetic eVects and various lifestyle
factors, such as smoking, a folate-deWcient diet, alcohol
intake and the use of medication, have been associated with
OFC (Jugessur and Murray 2005; Krapels et al. 2006a, b).
It is important to realize that the mother determines the
intrauterine environment in which the fetus develops. Our
aim was to investigate any association between MSX1-CA
markers in the mother, father, and child with periconcep-
tional smoking, alcohol, and medication use by both par-
ents and maternal folic acid supplementation in a Dutch
population.
Materials and methods
Study population
The study population and design were described previ-
ously (van Rooij et al. 2002). BrieXy, between 1998 and
2000, a case-control triad study was conducted by nine of
the largest cleft palate teams in the Netherlands (Amster-
dam VU, Arnhem, Groningen, Leeuwarden, Nijmegen,
Rotterdam, Tilburg, Utrecht, and Zwolle). We recruited
children with a nonsyndromic OFC, both parents, and
healthy controls. In each hospital team, the OFC was diag-
nosed by a clinician according to a standard registration
form developed by the Dutch Association for Cleft Palate
and Craniofacial Anomalies (Luijsterberg and Vermeij-
Keers 1999). The standardized registration was performed
when the index child was approximately 15 months old.
Most associated malformations and developmental delays
are identiWed in the Wrst year of life, which is important in
selecting cases and controls. The unrelated control children
did not have major congenital malformations and were
enrolled by friends, acquaintances or neighbors of case
parents and through well-baby clinics in and around Nij-
megen. (Dutch well-baby clinics provide standard check-
ups for all young children’s growth and development.) All
participants were Dutch Caucasians. DNA was obtained
via blood samples or buccal swabs. We deWned the per-
iconceptional period for mothers as 3 months before con-
ception to 3 months afterward and for the fathers as
3 months before conception to 2 weeks afterward. The peri-
conceptional period for recommended folic acid use is
deWned as 4 weeks before conception to 8 weeks after-
ward.
Both case and control parents Wlled in a questionnaire at
home on demographics and on their periconceptional and
Wrst-trimester smoking, alcohol consumption, medication
use and maternal folic acid supplementation. The mothers
were asked to Wll in questionnaires for the period covering
3 months before conception to 3 months afterward, while
the fathers reported on the period of 3 months before con-
ception to 2 weeks afterward. The questions on medication
use asked about the type of medication, dosage, and fre-
quency of intake, and the period in which medication was
taken.
Maternal folic acid supplementation was deWned as any
taken during the periconceptional period, with a daily
intake of at least 400 g of folic acid, either in a multivita-
min supplement or as a single tablet of folic acid from
4 weeks before conception to 8 weeks afterward, as recom-
mended by the Dutch government for all women who want
to become pregnant (Health Council and Food and Nutri-
tion Council 1993). There were also questions on the
mother’s periconceptional use of multivitamins with or
without folic acid.
Both parents were also asked about their family history
and if they reported any family member with an OFC, the
family history was deWned as positive.
We selected case and control children and their parents
for whom DNA was available and the MSX1 CA repeats
could be successfully analyzed. This resulted in 181 case
mothers and 132 control mothers, 155 case fathers and 121
control fathers, and 176 cases and 146 control children.
Due to the poor quality of the DNA isolated from a number
of buccal swabs, CA repeat data were only available for
107 complete case triads and for 66 complete control triads
to be included in our TDT analysis.123
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A venous blood sample was taken from the mothers to mea-
sure their concentrations of serum and red blood cell (RBC)
folate. These were measured using a microbiologic assay.
Sample collection and laboratory determination were
described previously (van Rooij et al. 2003).
Genotyping
The analyses were based on an intronic polymorphic CA
repeat in the MSX1 gene. The CA repeat alleles were deter-
mined by polymerase chain reaction (PCR) and fragment
analysis. Primers and conditions for PCR were as
described previously, with minor modiWcations (Hwang
et al. 1998). After amplifying the DNA, PCR products
were run on an ABI 3100 sequencer (Applied Biosystems)
and analyzed using genescan and genotyper software
(Applied Biosystems). Sequencing analysis was performed
on representative samples to determine the exact repeat
numbers for diVerent alleles (data not shown). Four diVer-
ent alleles could be identiWed and were called as in previ-
ous studies: allele 1, 12 CA repeats; allele 2, 11 CA
repeats; allele 3, 10 CA repeats; allele 4, 9 CA repeats
(Jugessur et al. 2003).
Statistical analysis
Sample characteristics were compared between cases and
controls using t test or Chi-square tests. The frequencies of
the four MSX1 CA repeat alleles were compared between
cases and controls, and odds ratios (OR) were derived with
95% conWdence intervals (CI), for which allele 1 served as
the reference. To test for genetic association in nuclear
families, we used the software package UNPHASEDv2.4,
which implements a likelihood-based approach allowing
for missing parental data (Dudbridge 2008).
The genotypes for the MSX1 CA repeat were allotted to
three genotype categories deWned in previous studies: CA4
homozygotes (4/4), CA4 heterozygotes (4/x), and CA4
non-carriers (x/x) (Beaty et al. 2002; Fallin et al. 2003; Jug-
essur et al. 2003). Genotypic odds ratios with 95% CI were
derived. We investigated gene–environment interactions by
further stratifying environment factors such as parental
smoking, alcohol consumption, medication use, and mater-
nal folic acid supplementation.
Because CA4 is the most common allele, the groups of
non-exposed CA4 non-carriers were too small to serve as a
reference. We therefore combined CA4 heterozygotes and
CA4 non-carriers (4/x, x/x) into one category for all the
stratiWed and non-stratiWed analyses. The limited sample
size meant stratiWed analyses of the diVerent OFC pheno-
types were not feasible.
Pooling diVerent types of clefting is consistent with the
Wnding that MSX1 is involved in both CL/P and CPO (van
den Boogaard et al. 2000). Furthermore, a recent study
identiWed occult lip defects with high-resolution ultrasound
of the upper lip in a subset of CP cases, showing how diY-
cult it is to classify orofacial clefting in diVerent types
(Weinberg et al. 2008).
The data for folic acid values were compared between
the groups using Wilcoxon’s rank sum test.
Results
Characteristics
The characteristics of the case and control groups are given
in Table 1. Case children were almost twice as likely to be
boys compared to controls (OR 1.8, 95% CI 1.1–2.8), con-
sistent with the large number of CL/P cases and known male
predominance (Jugessur et al. 2003). There were no signiW-
cant diVerences in the characteristics of parents and children
between the cases and controls, except that a positive family
history was reported signiWcantly more frequently by case
parents compared to controls (both P < 0.01).
In the periconceptional period, case mothers used sig-
niWcantly more medication (P < 0.01) and case fathers
smoked more than controls (P = 0.05). However, maternal
medications were rather diverse and included analgesics,
decongestive nose-sprays, antibiotics, antimycotics, anti-
histamic drugs, ovulation-inducing drugs, antidepressive
drugs and thyroid drugs. No anti-epileptic drugs, nor vita-
min A or its congeners, were reported.
There was no signiWcant diVerence in the use of folic acid
between case and control mothers. In total, 62.8% of case
mothers and 71.8% of control mothers took some folic acid
in the periconceptional period. However, when maternal
folic acid supplementation was deWned as daily use from
4 weeks before conception to 8 weeks afterward, case moth-
ers took signiWcantly less folic acid supplementation. Of
those who took supplements, all but one mother used 400 g
folic acid; this case mother took 5 mg folic acid daily during
the recommended period without clear indication.
Serum and red blood cell folate levels
The median serum and red blood cell (RBC) folate concen-
trations were within the normal range (>4.8 and >340 nmol/L,
respectively) (van Rooij et al. 2003) (Table 2). The
median level of serum folate was lower in the case mothers
than in control mothers, 13.2 and 15.2 nmol/L. The median
level of serum folate was lower in mothers who smoked
during the periconceptional period than in non-smoking
mothers, 12.7 and 14.0 nmol/L. In mothers who smoked123
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folate was lower, 11.3 nmol/L, than in non-smoking 4/4
mothers, 13.0 nmol/L. In addition, the median level of
serum folate was lower in case mothers who smoked and
who had the 4/4 genotype than in those smoking case moth-
ers not carrying the 4/4 genotype (category 4/x, x/x), 11.3
and 14.5 nmol/L.
The median RBC folate concentrations also revealed no
signiWcant diVerences. The median RBC folate level in case
mothers was 654.5 nmol/L, while it was 634.8 nmol/L in
control mothers. The median RBC folate in mothers who
smoked during the periconceptional period was 641.8 nmol/L,
and in non-smoking mothers it was 637.8 nmol/L. The RBC
folate concentration was lower in mothers who smoked and
had the 4/4 genotype than in non-smoking 4/4 mothers,
527.6 and 594.0 nmol/L, respectively. Furthermore, the
median level of RBC folate was lower in case mothers who
smoked and had the 4/4 genotype than in case mothers who
smoked but did not have the 4/4 genotype (category 4/x, x/
x), 554.9 and 681.9 nmol/L, respectively.
CA repeat alleles and MSX1 genotypes
As in previous studies, four alleles were identiWed (Juges-
sur et al. 2003). The distributions of the CA repeat alleles
and genotypes were not signiWcantly diVerent among case
Table 1 Characteristics of the case and control triads
SD standard deviation, CL/P cleft lip with or without cleft palate, CL cleft lip, CP cleft palate, CLP cleft lip with cleft palate; OFC orofacial clef-
ting; OR (95% CI) = odds ratio, 95% conWdence interval; n = number for whom MSX1 CA repeat alleles were successfully analyzed; P value tested
by Chi-square
a At delivery of the child
b Any smoking/cigarettes/cigar/pipe
c Any alcohol use
d Any medication other than oral contraceptives or iron
e Any use of supplements containing folic acid
f Daily use of supplements containing folic acid with a minimum of 400 g folic acid from 4 weeks before conception to 8 weeks afterward, one
case mother used 5 mg per day. Incidental users and women who started folic acid supplements later than 4 weeks before conception were excluded
Cases % Missing Controls % Missing OR (95% CI) P value
Child n = 176 n = 146
Age at the study moment in months, mean (SD) 15.2 4.2 2 14.7 6.7 6 0.43
Boys, n (%) 114 64.8 74 50.7 1.8 (1.1–2.8) 0.01
Boys in CL/P cases, n (%) 102 68.0 74 50.7 2.1 (1.3–3.4) <0.01
Boys in CP cases, n (%) 12 46.2 74 50.7 0.8 (0.4–1.9) 0.65
Type of OFC
CL, n (%) 58 33.0
CP, n (%) 26 14.8
CLP, n (%) 92 52.3
Mother n = 181 n = 132 0.54
Age, years, mean (SD)a 30.6 3.9 1 30.9 3.8 3
Family history for OFC positive, n (%) 38 21.1 1 11 8.4 1 <0.01
Periconception, yes, n (%)
Smokingb 52 28.9 1 27 20.6 1 1.6 (0.9–2.7) 0.10
Alcoholc 68 37.8 1 60 45.8 1 0.7 (0.5–1.1) 0.16
Medicationd 68 37.8 1 26 19.9 1 2.5 (1.5–4.1) <0.01
Any folic acid usee 113 62.8 1 94 71.8 1 0.7 (0.4–1.1) 0.10
Folic acid use/multivitamin usef 54 44.6 60 56 60.2 39 0.5 (0.3–0.9) 0.02
Father n = 155 n = 121 1
Age, years, mean (SD) 33.1 4.1 3 33.8 4.8 0.21
Family history for OFC positive, n (%) 33 21.9 4 10 8.5 3 <0.01
Periconception, yes, n (%)
Smokingb 73 47.7 2 43 35.8 1 1.6 (1.0–2.7) 0.05
Alcoholc 137 89.5 2 105 87.5 1 1.2 (0.6–2.6) 0.60
Medicationd 26 17.0 2 12 10.0 1 1.8 (0.9–3.8) 0.10123
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repeats of the CA marker in the MSX1 allele) was the most
common allele in case children (58.0%), mothers (57.7%),
and fathers (53.9%), and in control children (56.1%), moth-
ers (53.4%), and fathers (55.8%), regardless of OFC status
(Fig. 1; Table 3).
For the TDT analysis, we analyzed 107 informative case
triads. Case fathers transmitted allele 1 on three occasions
but did not transmit allele 1 on 14 occasions (P = 0.02).
Genotype 1/4 was seen less frequently in cases than in
controls (OR 0.47, 95% CI 0.2–1.1). However, the fre-
quency of allele 1 was low and the numbers were too small
for further analysis.
Interactions between lifestyle factors and MSX1 genotypes
Gene–environment interaction analysis for parental and
child genotype and parental smoking, alcohol use, medica-
tion use and maternal folic acid supplement use was per-
formed and is shown in Tables 4 and 5.
Maternal smoking inXuenced the risk for OFC if either
the child or mother was homozygous for allele 4 (OR 2.7,
95% CI 1.1–6.6 and OR 3.2, 95% CI 1.1–9.0, respectively)
(Table 4). If both parents smoked, the odds ratio was
increased to 4.9 (95% CI 1.4–18.0) (Table 4). The possible
eVects of paternal smoking are presented in Table 4. Chil-
dren homozygous for allele 4 of fathers who smoked
showed a more than twofold increased OFC risk (OR 2.2,
95% CI 1.0–4.7). When we excluded the children with two
Table 2 Plasma and red blood 
cell folate concentrations in rela-
tion to smoking and MSX1 geno-
type
Case mothers Control mothers P value*
n = 101 n = 80
Median (p5–p95) Median (p5–95)
Plasma folate (nmol/L) 13.2 (5.7–38.6) 15.2 (6.8–58.3) 0.40
n = 103 n = 82
Red blood cell folate 
(nmol/L)
654.5 (325.6–1226.5) 634.8 (348.3–1418.6) 0.61
Smoking mothers Non-smoking mothers P value*
n = 44 n = 136
Median (p5–p95) Median (p5–p95)
Plasma folate (nmol/L) 12.7 (5.2–38.6) 14.0 (6.6–55.9) 0.30
n = 44 n = 139
Red blood cell folate 
(nmol/L)
641.8 (266.8–1182.2) 637.8 (342.8–1401.9) 0.26
Smoking 4/4 mothers Non-smoking 4/4 mothers P value*
n = 12 n = 46
Median (p5–p95) Median (p5–p95)
Plasma folate (nmol/L) 11.3 (5.1–26.5) 13.0 (5.9–48.2) 0.19
n = 12 n = 46
Red blood cell folate 
(nmol/L)
527.6 (165.7–1024.9) 594.0 (363.5–1446.1) 0.16
Smoking 4/4 case mothers Smoking 4/x, x/x case mothers P value*
n = 10 n = 20
Median (p5–p95) Median (p5–p95)
Plasma folate (nmol/L) 11.3 (5.1–26.5) 14.5 (5.1–38.7) 0.19
n = 10 n = 20
Red blood cell folate 
(nmol/L)
554.9 (165.7–1024.9) 681.9 (246.7–1204.4) 0.59
* Wilcoxon’s rank sum test
Fig. 1 Allele frequencies (%) in case and control child, mother, and
father123
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(95% CI 0.5–3.2).
An association was found between the mother not taking
folic acid supplements and increased OFC risk (Table 5a,
b). Not taking folic acid daily in the recommended period
increased OFC risk for children homozygous for allele 4 (4/
4) (OR 2.0, 95% CI 0.9–4.5) as well as for children not car-
rying the 4/4 genotype (category 4/x, x/x) (OR 1.4, 95% CI
0.7–2.7) (Table 5a). In addition, not taking folic acid sup-
plements daily during the recommended period increased
the risk of having a child with OFC in both mothers homo-
zygous for allele 4 (4/4) (OR 2.8, 95% CI 1.1–6.7) and in
mothers without the 4/4 genotype (category 4/x, x/x) (OR
1.8, 95% CI 0.96–3.5) (Table 5a). Only a relatively small
number of mothers (54 case mothers and 56 control mothers)
took the advised 400 g folic acid daily in the recom-
Table 3 Case-control genotype distribution of the MSX1 CA repeat in
children, mothers and fathers in association with risk of orofacial
clefting
a Combined genotype category, x = allele 1, 2, 3
Genotype No. of 
cases
% No. of 
controls
% OR (95% CI)
Child n = 176 n = 146
4/4 56 31.8 45 30.8 1.1 (0.7–1.7)
4/x, x/xa 120 68.2 101 69.2 1.0 (Reference)
Mother n = 181 n = 132
4/4 61 33.7 33 25.0 1.5 (0.9–2.5)
4/x, x/xa 120 66.3 99 75.0 1.0 (Reference)
Father n = 155 n = 121
4/4 44 28.4 37 30.6 0.9 (0.5–1.5)
4/x, x/xa 111 71.6 84 69.4 1.0 (Reference)
Table 4 Interaction between 
parental smoking during per-
iconceptional period and the 
MSX1 CA repeat genotype on 
the risk of orofacial clefting
Genotype Smoking No. of cases % No. of controls % OR (95% CI)
Child Mother n = 175 n = 145
4/4 Yes 23 13.1 7 4.8 2.7 (1.1–6.6)
4/x, x/xa Yes 30 17.1 28 19.3 0.9 (0.5–1.6)
4/4 No 33 18.9 38 26.2 0.7 (0.4–1.2)
4/x, x/xa No 89 50.9 72 49.7 1.0 (Reference)
Child Father n = 172 n = 143
4/4 Yes 28 16.3 12 8.4 2.2 (1.0–4.7)
4/x, x/xa Yes 55 32.0 39 27.3 1.3 (0.8–2.3)
4/4 No 26 15.1 33 23.1 0.7 (0.4–1.4)
4/x, x/xa No 63 36.6 59 41.3 1.0 (Reference)
Child Fatherb n = 119 n = 108
4/4 Yes 12 10.1 9 8.3 1.2 (0.5–3.2)
4/x, x/xa Yes 32 26.9 18 16.7 1.7 (0.8–3.3)
4/4 No 19 16.0 29 26.9 0.6 (0.3–1.2)
4/x, x/xa No 56 47.0 52 48.1 1.0 (Reference)
Child Mother + fatherc n = 114 n = 105
4/4 Yes 16 14.0 3 2.9 4.9 (1.4–18.0)
4/x, x/xa Yes 23 20.2 21 20.0 1.0 (0.5–2.1)
4/4 No 19 16.7 29 27.6 0.6 (0.3–1.2)
4/x, x/xa No 56 49.1 52 49.5 1.0 (Reference)
Mother n = 180 n = 131
4/4 Yes 18 10.0 5 3.8 3.2 (1.1–9.0)
4/x, x/xa Yes 34 18.9 22 16.8 1.4 (0.7–2.5)
4/4 No 42 23.3 28 21.4 1.3 (0.8–2.3)
4/x, x/xa No 86 47.8 76 58.0 1.0 (Reference)
Father n = 153 n = 120
4/4 Yes 22 14.4 12 10.0 1.6 (0.7–3.6)
4/x, x/xa Yes 51 33.3 31 25.8 1.5 (0.8–2.6)
4/4 No 21 13.7 25 20.8 0.7 (0.4–1.5)
4/x, x/xa No 59 38.6 52 43.3 1.0 (Reference)
OR 95% CI = odds ratios 95% 
conWdence interval
a Combined genotype category 
x = allele 1, 2, 3
b Independent eVect of smoking 
by the father, children of two 
smoking parents were excluded
c Mother + father; yes both par-
ents smoking, no both parents 
not smoking123
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mothers taking any folic acid supplements at all (Table 5b).
During pregnancy, case mothers more often took medi-
cation (OR 2.5, 95% CI 1.5–4.1) (Table 1). The OFC risk
was higher in mothers or their children homozygous for
allele 4 if the mother used medication (OR 8.3, 95% CI
2.4–28.7 and OR 1.9, 95% CI 0.9–4.0, respectively), albeit
not signiWcantly in the children. If fathers used medication
and they or their children were homozygous for allele 4, the
OFC risk was also increased, albeit not signiWcantly (OR
3.3, 95% CI 0.9–12.0 and OR 1.2, 95% CI 0.5–3.1, respec-
tively). We found no signiWcant interactions between the 4/
4 genotype in mothers, fathers, or children, parental alcohol
use and OFC risk (data not shown).
Discussion
This study provides further evidence for an association
between the homeobox gene MSX1 and maternal smoking
during the Wrst trimester of pregnancy and oVspring with
nonsyndromic OFC. In addition, the daily use of folic acid
supplement from 4 weeks before conception to 8 weeks
afterward reduces OFC risk independent of MSX1 geno-
type. The analyses are based on an intronic polymorphic
CA repeat in the MSX1 gene, which identiWes four alleles.
Consistent with previous observations, allele 4 (nine
repeats of the CA marker in the MSX1 allele) was the most
common allele (Jugessur et al. 2003). Our analysis suggests
that allele 4 homozygous (4/4) children exposed to pericon-
ceptional smoking by both parents, but particularly by the
mother, are more susceptible to OFC. The maternal 4/4
genotype and smoking showed a threefold higher OFC risk.
Several hypotheses might explain the mechanisms by
which interaction between smoking and MSX1 inXuences
OFC risk. Studies in mice suggest that maternal cigarette
smoke alters the expression of a large number of genes in the
fetus. Especially genes involved in response to oxidative
stress, DNA and protein repair, signal transduction and cell
cycle regulation (CDK4 and CDK6 inhibitors) were upregu-
lated (Izzotti et al. 2003). Interestingly, Msx1 permits cell
cycle progression and proliferation of tissue by inhibiting the
expression of CDK inhibitors, resulting in E2F mediated
expression of cell cycle genes (Han et al. 2003).
Treatment of mouse hepatoma cells with a component of
tobacco smoke [2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)]
Table 5 Folic acid use, MSX1 
CA repeat genotype and risk of 
orofacial clefting
a. Interaction between maternal folic acid use in the recommended periconceptional 
period and MSX1 CA repeat genotype on the risk of orofacial clefting
Genotype Folic acidb No. of cases % No. of controls % OR (95% CI)
Child Mother n = 117 n = 106
4/4 No 23 19.7 13 12.3 2.0 (0.9–4.5)
4/x, x/xa No 44 37.6 35 33.0 1.4 (0.7–2.7)
4/4 Yes 15 12.8 19 17.9 0.9 (0.4–2.0)
4/x, x/xa Yes 35 29.9 39 36.8 1.0 (Reference)
Mother n = 121 n = 93
4/4 No 22 18.2 9 9.7 2.8 (1.1–6.7)
4/x, x/xa No 45 37.2 28 30.1 1.8 (0.96–3.5)
4/4 Yes 16 13.2 13 14.0 1.4 (0.6–3.3)
4/x, x/xa Yes 38 31.4 43 46.2 1.0(Reference)
b. Interaction between some maternal folic acid use during pregnancy and MSX1 CA 
repeat genotype on the risk of orofacial clefting
Genotype Folic acidc No. of cases % No. of controls % OR (95% CI)
Child Mother n = 175 n = 145
4/4 No 23 13.1 13 9.0 1.5 (0.7–3.3)
4/x, x/xa No 44 25.1 35 24.1 1.1 (0.6–1.9)
4/4 Yes 33 18.9 32 22.1 0.9 (0.5–1.6)
4/x, x/xa Yes 75 42.9 65 44.8 1.0 (Reference)
Mother n = 180 n = 131
4/4 No 22 12.2 9 6.9 2.3 (0.98–5.3)
4/x, x/xa No 45 25.0 28 21.4 1.5 (0.9–2.7)
4/4 Yes 38 21.1 24 18.3 1.5 (0.8–2.7)
4/x, x/xa Yes 75 41.7 70 53.4 1.0 (Reference)
OR odds ratios, 95% CI 95% 
conWdence interval
a Combined genotype category 
x = allele 1, 2, 3
b Daily use of supplements con-
taining folic acid (400–500 g) 
from 4 weeks before conception 
of the child until 8 weeks after; 
incidental users and women who 
started folic acid supplements 
later than 4 weeks before con-
ception were excluded
c Any folic acid use during preg-
nancy, also incidental users and 
women who started folic acid 
supplements later than 4 weeks 
before conception were included123
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genes necessary for cell cycle progression (Huang and Elfer-
ink 2005).
Another interesting hypothesis is that AhR suppresses
Tgfb3 expression and Tgfb3 has an indirect eVect on IRF6.
Various studies have shown that both genes play a signiWcant
role in the development of the palate and lip (Murray and
Schutte 2004). The Wnding of two IRF binding sites in the
promotor and intron of MSX1 indicates both genes might be
part of a common pathway (Kondo et al. 2002). This would
suggest that there is a relation between Ahr and MSX1, and
thus indirectly between smoking and MSX1. The eVect of the
interaction between smoking and MSX1 might also be a
result of gene–gene interaction with genes involved in detoxi-
Wcation pathways. Results of a preliminary analysis sug-
gested gene–gene interaction between MSX1 with CYP1B1,
GSTM1, HIF1A, and SULT1A1 (Shi et al. 2007).
Another aspect of smoking by the mother is its possible
inXuence on folate levels. It has been suggested that expo-
sure to tobacco smoke decreases serum folate level and that
these lower levels are not completely due to diVerences in
folate intake from diet or supplements (Mannino et al. 2003;
Honein et al. 2007). In our study the current level of serum
folate was also lower in the mothers who smoked during the
periconceptional period than in the non-smoking mothers.
This was in contrast to the RBC folate levels. The smoking
mothers with the 4/4 genotype had a lower serum and RBC
folate level than non-smoking 4/4 mothers. In addition, the
level of serum and RBC folate was lower in the case moth-
ers who smoked and had the 4/4 genotype than in the case
mothers who smoked without this genotype. However, the
numbers are too small to draw any Wrm conclusions.
Interestingly, knockout studies in mice demonstrated
inactivation of the folate-binding protein Folbp1, decreased
folate levels and clefting (Tang and Finnell 2003). The Shh
expression was decreased in the facial primordial in the
Folbp1 mutants, accompanied by an increase of Bmp4
expression. It is striking that Msx1 plays a signiWcant role
in the expression of Bmp4, and that Msx1, Bmp4, Shh and
Bmp2 constitute a pathway essential in the palatogenesis in
mice (Zhang et al. 2002). Pax3 was also found to be upregu-
lated in the nasal processes of the Folbp1 mutant (Tang and
Finnell 2003). In vivo studies showed that complex forma-
tion between MSX1 and PAX3 may prevent premature
activation of myogenic genes (MyoD) in muscle precursor
cells, which is important for the maintenance of their prolif-
erative capacity and outgrowth (Bendall and Abate-Shen
2000). We speculate that low levels of folate might inXu-
ence the function of speciWc MSX1 variants, thereby aVect-
ing the MSX1, BMP4, SHH and BMP2 pathway in the
embryo. The downregulation of SHH aVects the expression
of PAX3, resulting in abnormal outgrowth of tissue. Further
studies are needed to evaluate these possible mechanisms
and the speciWc role of MSX1 in these models in relation to
OFC.
An interesting aspect of folic acid is that it functions as a
one-carbon donor for DNA methylation, which is important
in regulating gene expression. A recent study indicated
expression of Msx1 in embryonic stem cells was regulated
by a unique histone modiWcation, which consisted of activating
and repressive methylation within their promotor loci (Gan
et al. 2007). We cannot rule out that low folate aVects this
mechanism as well, and it might explain potential associa-
tions between smoking, folic acid, MSX1 and OFC risk.
In this study, only a relatively small number of mothers
took the daily 400 g folic acid in the recommended period.
Association between supplemental folic acid use, MSX1
and OFC risk was observed. Homozygosity for allele 4 in
the child or mother combined with the mother not taking
folic acid supplements tended to increase OFC risk. How-
ever, any interaction between periconceptional folic acid
intake and a speciWc MSX1 genotype on OFC risk will have
a relatively small eVect.
Our case fathers smoked more often than control fathers,
and paternal smoking may also contribute to OFC risk.
Paternal smoking increases maternal exposure to tobacco
smoke by passive smoking, thus indirectly inXuencing the
environment of the fetus. Homozygosity for allele 4 in chil-
dren and paternal smoking showed a twofold higher OFC
risk. However, to exclude any possible eVect from the
mother smoking, we performed an additional analysis
which excluded children with two smoking parents. The
suggested interaction between paternal smoking, homozy-
gosity for allele 4 in the child and OFC risk could not be
conWrmed. But again, our sample size was very small.
In all our analyses we used the intronic CA repeat
marker. Recent studies (Knight 2004; Spielman et al. 2007)
have revealed that polymorphic variants can also be respon-
sible for individual diVerences in expression level, and spe-
ciWc genetic variation among populations contributes
appreciably to diVerences in gene expression phenotypes.
These variations of gene expression and speciWc gene
expression phenotypes could account for a large proportion
of susceptibility to complex genetic disorders (Spielman
et al. 2007). Given this observation, the CA repeat may also
play a role in the etiology of clefting. The Msx1 gene
encodes an antisense RNA, which regulates gene expres-
sion, and the antisense strand, in the 3UTR to the middle
of the intron, includes the CA repeat (Blin-Wakkach et al.
2001). We hypothesize that diVerences in the CA repeat
numbers of the opposite alleles may alter the binding
between the sense and antisense RNA molecules of both
alleles and could thereby aVect regulation of gene expres-
sion. This could be an explanation for the possibly protective
eVect of the 1/4 genotype and our Wnding that this genotype
was more prevalent in controls than in cases. The diVerence123
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found in the 1/4 genotype, which may inXuence regulation
of gene expression by antisense RNA. Further studies are
needed to evaluate this possible mechanism.
We performed our study using a case-control study
design, in which recall bias of periconceptional exposure
must be considered. To minimize this issue, we used a stan-
dardized study moment, when the child was around
15 months old for both the case and control groups. This
moment is in the same season as the periconceptional period
and just after the Wrst birthday, which may facilitate parents’
recall. However, several studies have indicated that the role
of recall bias in case-control studies focusing on congenital
malformations can be considered fairly small (Infante-Rivard
and Jacques 2000) and our data on lifestyle exposures of the
reproductive age group also correspond with those reported
in the Dutch population (Statistics Netherlands 2003).
In conclusion, we demonstrate a complex role for the
MSX1 gene, maternal smoking, and folic acid intake in the
etiology of OFC and show some interesting gene–environ-
ment interactions that inXuence the risk of OFC. Further
studies are needed to resolve the details of the pathogenic
mechanisms and to determine the genetic and environmental
risk factors playing a decisive role in the occurrence of OFC.
Ultimately, this work may be helpful in providing better tai-
lored advice to individuals in preconceptional counseling.
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